Patents Assigned to Pharmacore, Inc.
  • Patent number: 7507830
    Abstract: Methods are provided for the construction of unsymmetrical biaryl compounds and alkylated aromatic compounds from arylnitriles using a nickel or palladium catalyzed coupling in which the catalyst has at least one phosphine or phosphite ligand.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: March 24, 2009
    Assignee: Pharmacore, Inc.
    Inventor: Joseph A. Miller
  • Patent number: 7105467
    Abstract: The present invention provides nickel catalysts and solvents which are useful in a cross-coupling reaction between an organomagnesium compound and an aromatic ether compound, such as an anisole derivative.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: September 12, 2006
    Assignee: Pharmacore, Inc.
    Inventor: John W. Dankwardt
  • Patent number: 7105707
    Abstract: Mono- and disubstituted aryl or heterocyclic acetylenes are produced by a process comprising reacting an aryl nitrile with an alkynylzinc compound, a bis-alkynylzinc compound, or an alkynylmagnesium compound, in the presence of a nickel/phosphine catalyst.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: September 12, 2006
    Assignee: PharmaCore, Inc.
    Inventors: Joseph A. Miller, Jonathan M. Penney
  • Patent number: 6962999
    Abstract: Methods are provided for the construction of unsymmetrical biaryl compounds and alkylated aromatic compounds from arylnitriles using a nickel or palladium catalyzed coupling in which the catalyst has at least one phosphine or phosphite ligand.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: November 8, 2005
    Assignee: Pharmacore, Inc.
    Inventor: Joseph A. Miller
  • Patent number: 6930200
    Abstract: Mono-substituted and di-substituted alpha-amino acids and derivatives thereof, substituted at the alpha positon with one (mono-) or two (di-) substituents (R2 and/or R3) as shown in Formula 1: N(R4R5)C(R2R3)CO(OR1).
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: August 16, 2005
    Assignee: Pharmacore, Inc.
    Inventor: Adnan M. M. Mjalli
  • Patent number: 6809207
    Abstract: The present invention provides certain alpha-amino acids and derivatives thereof, such as, but not limited to, esters, amides and salts. These derivatives may comprise such representative side groups as a phenyl, pyridyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, or thienyl group. The present invention further provides a method for synthesizing alpha-amino acids and derivatives thereof via a modified Ugi type reaction using an aldehyde, ammonium formate and a C1-C5 alkyl isocyanide. The compounds provided by this method are useful in the development of new pharmaceuticals for the treatment of human diseases.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: October 26, 2004
    Assignee: PharmaCore, Inc.
    Inventors: Sekar Alla, Seung-Yong Choi, Dale Dhanoa, Elso DiFranco, Galina Krokhina, Keqiang Li, Balasubramanian Thiagarajan, Wen-Chun Zhang
  • Patent number: 6713580
    Abstract: The present invention relates to novel templates useful for generating novel compounds and to compounds produced utilizing the templates. The templates comprise quaternary amino acids that may be linked to solid supports. These templates make possible the production of novel classes of chemical compounds through a plurality of chemical reactions. The templates are advantageous for use in drug discovery regimes.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 30, 2004
    Assignee: Pharmacore, Inc.
    Inventors: Michael Johnson, Keqiang Li, Elso DiFranco, Daljit S. Dhanoa
  • Patent number: 6677367
    Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: January 13, 2004
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Gilles Sauvé, Abderrahim Bouzide, Alexandre Coté, Gervais Bérubé, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
  • Patent number: 6656965
    Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: December 2, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Gilles Sauvé, Abderrahim Bouzide, Alexandre Coté, Gervais Bérubé, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
  • Patent number: 6638921
    Abstract: A compound of formula I and pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: October 28, 2003
    Assignee: Pharmacor Inc.
    Inventors: Gilles Sauvé, Brent Richard Stranix
  • Patent number: 6632816
    Abstract: The present invention provides HIV aspartyl protease inhibitors of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may be, for example, iso-butyl, wherein X and Y, same or different, may be, for example, NH2 and F, and wherein R2 and R3 are as defined herein.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: October 14, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Jean-François Lavallée, Nicolas LeBerre, Valérie Perron
  • Patent number: 6610689
    Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: August 26, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Gilles Sauvé, Abderrahim Bouzide, Alexandre Coté, Gervais Bérubé, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
  • Patent number: 6608100
    Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: August 19, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Gilles Sauvé, Abderrahim Bouzide, Alexandre Coté, Gervais Bérubé, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
  • Patent number: 6528532
    Abstract: The present invention provides HIV aspartyl protease inhibitors of the formula: and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, Y is O, S, NH or N—CN, wherein Cx may be, for example COOH, or CH2OH, wherein R1 is selected from the group consisting of a benzenesulfonyl group of formula II as defined herein, wherein R2 may be, for example, iso-butyl, or 3-methylbutyl, and wherein R3 and R4 are as defined herein.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: March 4, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Abderrahim Bouzide, Gilles Sauvé
  • Patent number: 6528655
    Abstract: A compound of formula I′ and pharmaceutically acceptable derivatives thereof including, for example, where applicable or appropriate pharmaceutically acceptable salts thereof. Ar and Ar′ are aromatic or aryl type groups. The compounds have HIV integrase inhibitory properties. Ar, Ar′ and W may be as defined in the specification.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: March 4, 2003
    Assignee: Pharmacor, Inc.
    Inventors: Blaise Magloire N'Zemba, Gilles Sauvé, Guy Sévigny, Jocelyn Yelle
  • Patent number: 6506786
    Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: January 14, 2003
    Assignee: Pharmacor Inc.
    Inventors: Brent Richard Stranix, Gilles Sauvé, Abderrahim Bouzide, Alexandre Coté, Gervais Bérubé, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
  • Patent number: 6455587
    Abstract: The present invention relates to a class of amino acid derivatives with HIV aspartyl protease inhibitory properties.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 24, 2002
    Assignee: Pharmacor Inc.
    Inventors: Abderrahim Bouzide, Gilles Sauvé, Brent Richard Stranix, Guy Sévigny, Jocelyn Yelle
  • Patent number: 6362165
    Abstract: An hydroxyphenyl derivative selected from the group consisting of a compound of formula and when a compound of formula I comprises a carboxylic acid group pharmaceutically acceptable salts thereof and when a compound of formula I comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein n is 1, 2 or 3, e is 1, 2 or 3, Hal represents a halogen atom (e.g. Cl, Br, F or I), p is 0, 1 or 2, r is 0, 1 or 2, X and X′ each independently represents a single bond, a saturated straight or branched hydrocarbon group of 1 to 4 carbon atoms or a straight or branched hydrocarbon group of 2 to 4 carbon atoms comprising a carbon to carbon double bond, Ra represents H or —CH3, and Raa represents H or —CH3; W may represent an amino acid residue or fragment. These compounds may be used to inhibit the activity of HIV integrase.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: March 26, 2002
    Assignee: Pharmacor Inc.
    Inventors: Gilles Sauvé, Jocelyn Yelle
  • Patent number: 6313177
    Abstract: A D-mannitol derivative selected from the group consisting of a compound of formula pharmaceutically acceptable derivatives thereof and where applicable or appropriate pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are the same or different and may each independently be selected from among alkyl and aryl (i.e. aromatic including aromatic like) groups. The D-mannitol derivatives may be used as HIV aspartyl protease inhibitors.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: November 6, 2001
    Assignee: Pharmacor Inc.
    Inventors: Gilles Sauvé, Abderrahim Bouzide